stockportfolio.pro
Stocks / CMPS vs PRCT
CMPS vs PRCT
COMPASS Pathways plc and PROCEPT BioRobotics Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| COMPASS Pathways plc (CMPS) | PROCEPT BioRobotics Corporation (PRCT) | |
|---|---|---|
| Market cap | $1.5B | $1.5B |
| Revenue (latest FY) | $0 | $308.05M |
| Net income (latest FY) | $-287.86M | $-95.57M |
| Revenue growth (5y CAGR) | — | 109.0% |
| Net margin | — | -31.0% |
| Return on equity | 544.7% | -26.1% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | — | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CMPS — free Open PRCT — freeFrequently asked questions
Which is bigger, CMPS or PRCT?
PROCEPT BioRobotics Corporation is larger by market capitalization — $1.5B versus $1.5B.
Which grows faster, CMPS or PRCT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.